PCI Pharma expands its serialization capability
The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.
PCI Pharma Services has announced a significant expansion of its serialization capability across the company's global supply network to support clients in advance of meeting both US DSCSA and EU FMD implementation dates.
The company has been actively serializing commercial products for both domestic and international markets for the past 5 years, with products destined for North America and Europe, in addition to emerging market geographies such as South Korea, Turkey, Brazil, China and others. In total, PCI supports medicines destined to over 100 global countries. The company's expansion triples its global serialization capacity in advance of upcoming DSCSA and FMD requirements.
PCI has partnered with Antares Vision, Marchesini and Domino for this latest installation, utilizing Antares’ leading serialization platform and technology architecture across a variety of serialization technology platforms and applications. The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.
In addition, serialization technologies support ancillary and tertiary packaging, corrugated shippers and palletization solutions for supporting multi-level product aggregation. Aggregation is technically not a requirement for compliance to the 2017 DSCSA deadline, however PCI has strongly supported the advanced use of aggregation to realize significant benefits in packaging operations as well as the broader pharmaceutical supply chain.
Commenting on the expansion, Vice President of Global Engineering, Ken Richardson shared: “Serialization preparedness is the topic on everyone’s mind in the pharmaceutical industry. We are very excited about the next phase of our global serialization initiative and brand security program here at PCI. Having active developed and supported serialization over the past 5 years with numerous commercial applications around the world, we have a significant body of knowledge to share with clients. With these key learnings from practical applications of Serialization and anti-counterfeiting technologies, we have positioned ourselves to support our clients as they start to truly develop their own global Serialization strategies.
“This latest investment is considerable, and features what we believe are truly industry-leading technologies. The spotlight is on the industry to meet the November deadline and PCI has directed an amazing amount of financial resource, technological expertise and manpower to help our clients be prepared.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance